Therapy of chronic obstructive pulmonary disease

Pharmacology and Therapeutics

Volumn 97, Issue 1, 2003, Pages 87-94

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Anticholinergic; COPD; Corticosteroid; Long term oxygen therapy; Phosphodiesterase 4 inhibitor; Theophylline; 2 Agonists

Indexed keywords

AMFEBUTAMONE; ANTIOXIDANT; BAMBUTEROL; BENZODIAZEPINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; DIGOXIN; DIHYDROCODEINE; DIURETIC AGENT; DOXAPRAM; FORMOTEROL; INFLUENZA VACCINE; INTERLEUKIN 8 ANTAGONIST; IPRATROPIUM BROMIDE; OPIATE DERIVATIVE; OSELTAMIVIR; PHOSPHODIESTERASE IV INHIBITOR; PNEUMOCOCCUS VACCINE; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; SALBUTAMOL; SALMETEROL; SIALIDASE INHIBITOR; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANAMIVIR; CORTICOSTEROID; OXYGEN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COR PULMONALE; COST BENEFIT ANALYSIS; DIET THERAPY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; ENZYME INHIBITION; EXERCISE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HUMAN; INFLUENZA VACCINATION; INTERMITTENT POSITIVE PRESSURE VENTILATION; LONG TERM CARE; LUNG FUNCTION; LUNG INFLATION; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; NAUSEA; NICOTINE REPLACEMENT THERAPY; OXIDATIVE STRESS; OXYGEN SATURATION; OXYGEN THERAPY; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SIDE EFFECT; SMOKING CESSATION; STREPTOCOCCUS PNEUMONIA; TREATMENT INDICATION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; XEROSTOMIA; ACUTE DISEASE; REVIEW;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; HUMANS; OXYGEN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY HEART DISEASE; SMOKING CESSATION;

EID: 0037215121     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00324-8     Document Type: Review

References (64)

1. Alsaeedi A., Sin D.D., McAlister F.A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 113:2002;59-65.
2. 2-agonists for chronic obstructive pulmonary disease. (Cochrane Review) The Cochrane Library, Issue 2, CD001104. 2000;Update Software, Oxford.
3. Barnes P.J. Molecular genetics of chronic obstructive pulmonary disease. Thorax. 54:1999;245-252.
4. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med. 343:2000;269-280.
5. Barnes P.J. Inhaled corticosteroids are not helpful in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 161:2000;342-344.
6. Barnes P.J. The pharmacological properties of tiotropium. Chest. 117:2000;63S-66S.
7. Barnes P.J. Future advances in COPD therapy. Respiration. 68:2001;441-448.
8. Barnes P.J. New treatments for chronic obstructive pulmonary disease. Curr Opin Pharmacol. 1:2001;217-222.
9. Barnes P.J. Tiotropium bromide. Expert Opin Invest Drugs. 10:2001;733-740.
10. Barnes P.J. New treatments for COPD. Nat Rev Drug Discov. 1:2002;437-445.
11. Burge P.S., Calverley P.M.A., Jones P.W., Spencer S., Anderson J.A., Maslen T. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial. Br Med J. 320:2000;1297-1303.
12. Calverley P.M.A., Pauwels R.A., Vestbo J., Jones P.W., Pride N.B., Gulsvik A., Anderson J., Clay M., Maden C. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual componenets in COPD. Am J Respir Crit Care Med. 165:2002;A226.
13. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San P.G., ZuWallack R.L., Menjoge S.S., Serby C.W., Witek T. Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 19:2002;217-224.
14. Compton C.H., Gubb J., Nieman R., Edelson J., Amit O., Bakst A., Ayres J.G., Creemers J.P., Schultze-Werninghaus G., Brambilla C., Barnes N.C. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet. 358:2001;265-270.
15. Crockett A.J., Moss J.R., Cranston J.M., Alpers J.H. Domicilary oxygen for chronic obstructive pulmonary disease. (Cochrane Review) The Cochrane Library, Issue 2, CD001744. 2000;Update Software.Cochrane, Oxford.
16. Crompton G.K., Ayres J.G., Basran G., Schiraldi G., Brusasco V., Eivindson A., Jamieson A.H., Olsson H. Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. Am J Respir Crit Care Med. 159:1999;824-828.
17. Culpitt S.V., Nightingale J.A., Barnes P.J. Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 160:1999;1635-1639.
18. Culpitt S.V., de Matos C., Russell R.E., Donnelly L.E., Rogers D.F., Barnes P.J. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in COPD. Am J Respir Crit Care Med. 165:2002;1371-1376.
19. Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 354:1999;456-460.
20. Dowling R.B., Johnson M., Cole P.J., Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J. 11:1998;86-90.
21. Faulkner M.A., Hilleman D.E. The economic impact of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 3:2002;219-228.
22. Ferreira I.M., Brooks D., Lacasse Y., Goldstein R.S. Nutritional supplementation in stable chronic obstructive pulmonary disease. (Cochrane Review) The Cochrane Library, Issue 2, CD000998. 2000;Update Software, Oxford.
23. Geddes D., Davies M., Koyama H., Hansell D., Pastorino U., Pepper J., Agent P., Cullinan P., MacNeill S.J., Goldstraw P. Effect of lung-volume-reduction surgery in patients with severe emphysema. N Engl J Med. 343:2000;239-245.
24. Griffiths T.L., Burr M.L., Campbell I.A., Lewis-Jenkins V., Mullins J., Shiels K., Turner-Lawlor P.J., Payne N., Newcombe R.G., Lonescu A.A., Thomas J., Tunbridge J. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet. 355:2000;362-368.
25. Gross N.J. The influence of anticholinergic agents on treatment for bronchitis and emphysema. Am J Med. 91:1991;11S-12S.
26. Jefferson T., Demicheli V., Deeks J., Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. (Cochrane Review) The Cochrane Library, Issue 2, CD001265. 2000;Update Software, Oxford.
27. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., Smith S.S., Muramoto M.L., Daughton D.M., Doan K., Fiore M.C., Baker T.B. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 340:1999;685-691.
28. Keatings V.M., Jatakanon A., Worsdell Y.M., Barnes P.J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 155:1997;542-548.
29. Lacasse Y., Wong E., Guyatt G.H., King D., Cook D.J., Goldstein R.S. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet. 348:1996;1115-1119.
30. Lancaster T., Stead L., Silagy C., Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. Br Med J. 321:2000;355-358.
31. Lopez A.D., Murray C.C. The global burden of disease, 1990-2020. Nat Med. 4:1998;1241-1243.
32. Loppow D., Schleiss M.B., Kanniess F., Taube C., Jorres R.A., Magnussen H. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med. 95:2001;115-121.
33. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 343:2000;1902-1909.
34. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol. 429:2001;195-207.
35. Montuschi P., Collins J.V., Ciabattoni G., Lazzeri N., Corradi M., Kharitonov S.A., Barnes P.J. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med. 162:2000;1175-1177.
36. Murciano D., Avclair M.-H., Parievte R., Aubier M. A randomized controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med. 320:1989;1521-1525.
37. Nichol K.L., Baken L., Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 130:1999;397-403.
38. Nichol K.L., Baken L., Wuorenma J., Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med. 159:1999;2437-2442.
39. Niewoehner D.E., Erbland M.L., Deupree R.H., Collins D., Gross N.J., Light R.W., Anderson P., Morgan N.A. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 340:1999;1941-1947.
40. O'Donnell D.E., Lam M., Webb K.A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 158:1998;1557-1565.
41. Paredi P., Kharitonov S.A., Leak D., Ward S., Cramer D., Barnes P.J. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 162:2000;369-373.
42. Pauwels R.A., Lofdahl C.G., Laitinen L.A., Schouten J.P., Postma D.S., Pride N.B., Ohlsson S.V. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 340:1999;1948-1953.
43. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med. 163:2001;1256-1276.
44. Perrin C., El Far Y., Vandenbos F., Tamisier R., Dumon M.C., Lemoigne F., Mouroux J., Blaive B. Domiciliary nasal intermittent positive pressure ventilation in severe COPD: effects on lung function and quality of life. Eur Respir J. 10:1997;2835-2839.
45. Plant P.K., Owen J.L., Elliott M.W. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet. 355:2000;1931-1935.
46. Rennard S.I., Serby C.W., Ghafouri M., Johnson P.A., Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest. 110:1996;62-70.
47. Romano P.M., Peterson S. The management of cor pulmonale. Heart Dis. 2:2000;431-437.
48. Russell R.E., Culpitt S.V., DeMatos C., Donnelly L., Smith M., Wiggins J., Barnes P.J. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 26:2002;602-609.
49. Saetta M., Di Stefano A., Maestrelli P., Turato G., Mapp C.E., Pieno M., Zanguochi G., Del Prete G., Fabbri L.M. Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy. 26:1996;766-774.
50. Saint S., Bent S., Vittinghoff E., Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA. 273:1995;957-960.
51. Scanlon P.D., Connett J.E., Waller L.A., Altose M.D., Bailey W.C., Buist A.S. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 161:2000;381-390.
52. Silagy C., Mint D., Fowler G., Ludge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet. 343:1994;139-142.
53. Smith K., Cook D., Guyatt G.H., Madhavan J., Oxman A.D. Respiratory muscle training in chronic airflow limitation: a meta-analysis. Am Rev Respir Dis. 145:1992;533-539.
54. Stockley R.A. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med. 160:1999;S49-S52.
55. Tamaoki J., Chiyotani A., Tagaya E., Sakai N., Konno K. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax. 49:1994;545-548.
56. Tarpy S.P., Celli B. Long-term oxygen therapy. N Engl J Med. 333:1995;710-714.
57. Tashkin D.P., Kanner R., Bailey W., Buist S., Anderson P., Nides M.A., Gonzales D., Dozier G., Patel M.K., Jamerson B.D. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo controlled, randomised trial. Lancet. 357:2001;1571-1575.
58. van Noord J.A., Bantje T.A., Eland M.E., Korducki L., Cornelissen P.J. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 55:2000;289-294.
59. Vestbo J., Sorensen T., Lange P., Brix A., Torre P., Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 353:1999;1819-1823.
60. Vincken W., van Noord J.A., Greefhorst A.P., Bantje T.A., Kesten S., Korducki L., Cornelissen P.J. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 19:2002;209-216.
61. Wedzicha J.A. Domiciliary oxygen therapy services: clinical guidelines and advice for prescribers. Summary of a report of the Royal College of Physicians. J R Coll Physicians Lond. 33:1999;445-447.
62. West R., McNeill A., Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 55:2000;987-999.
63. Wood-Baker R., Walters E.H., Gibson P. Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. (Cochrane Review) The Cochrane Library, Issue 2, CD001288. 2001;Update Software, Oxford.
64. ZuWallack R.L., Mahler D.A., Reilly D., Church N., Emmett A., Rickard K., Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 119:2001;1661-1670.